1893419-37-8
1893419-37-8
Chemical Structure
Dirozalkib
- CAS No.: 1893419-37-8
- Formula:C27H32ClN5O4S
- Molecular Weight:558.09
InChIKey: ABKQZNVWMCRCGQ-UHFFFAOYSA-N
SMILES: O=S(C1=C(NC2=NC(NC3=C4OCCOC4=C(C5CCNCC5)C(C)=C3)=NC=C2Cl)C=CC=C1)(C(C)C)=O
Biological Activity: Dirozalkib is an orally active and blood-brain barrier-penetrant ALK tyrosine kinase inhibitor. Dirozalkib inhibits the proliferation of ALK fusion-positive and ALK TKI-resistant tumor cells, and inhibits tumor growth in PDX and intracranial xenograft lung cancer models. Dirozalkib can be used for research related to non-small cell lung cancer[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Dirozalkib | Dirozalkib is an orally active and blood-brain barrier-penetrant ALK tyrosine kinase inhibitor. Dirozalkib inhibits the proliferation of ALK fusion-positive and ALK TKI-resistant tumor cells, and inhibits tumor growth in PDX and intracranial xenograft lung cancer models. Dirozalkib can be used for research related to non-small cell lung cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Ai X, et al. Preclinical characterization and first-in-human, phase I trial of the novel ALK inhibitor dirozalkib in advanced non-small cell lung cancer. European journal of cancer (Oxford, England : 1990). 2026 Feb 25;235:116221.
- [2]. Fang L, et al. Presence of drug-drug interactions between esomeprazole and an ALK tyrosine kinase inhibitor (Dirozalkib). Cancer chemotherapy and pharmacology. 2025 Dec 05;95(1):122.
- [3]. Liu Y, et al. Abstract CT243: Dirozalkib in patients with advanced ALK-positive non-small cell lung cancer (NSCLC): Results from a phase 2 study. Cancer Research. 2026 Apr 17;86(8_Supplement):CT243-.
